MD596Z - Метод лечения хронического вирусного гепатита С у детей - Google Patents
Метод лечения хронического вирусного гепатита С у детей Download PDFInfo
- Publication number
- MD596Z MD596Z MDS20120138A MDS20120138A MD596Z MD 596 Z MD596 Z MD 596Z MD S20120138 A MDS20120138 A MD S20120138A MD S20120138 A MDS20120138 A MD S20120138A MD 596 Z MD596 Z MD 596Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- glucopyranosyl
- hcv
- day
- children
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 208000005176 Hepatitis C Diseases 0.000 title claims abstract description 7
- 208000010710 hepatitis C virus infection Diseases 0.000 title claims abstract description 5
- 230000001684 chronic effect Effects 0.000 title claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 10
- 235000012054 meals Nutrition 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 abstract description 3
- 241000711549 Hepacivirus C Species 0.000 description 43
- 229930185631 capsicoside Natural products 0.000 description 25
- 206010058874 Viraemia Diseases 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 14
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 11
- 230000000840 anti-viral effect Effects 0.000 description 10
- 238000002559 palpation Methods 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 7
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000004596 appetite loss Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 235000021266 loss of appetite Nutrition 0.000 description 5
- 208000019017 loss of appetite Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010057248 Cell death Diseases 0.000 description 4
- 206010067482 No adverse event Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 229960004245 silymarin Drugs 0.000 description 3
- 235000017700 silymarin Nutrition 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 3
- 229960001661 ursodiol Drugs 0.000 description 3
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000208293 Capsicum Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 206010051914 Cholesterosis Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- JPXZQMKKFWMMGK-KQYNXXCUSA-K IDP(3-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-K 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000003947 acalculous cholecystitis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000016569 congenital mitral valve insufficiency Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- LELAOEBVZLPXAZ-UHFFFAOYSA-N iberin Chemical compound CS(=O)CCCN=C=S LELAOEBVZLPXAZ-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000286 interferogenic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к гепатологии, и может быть использовано для лечения хронического вирусного гепатита С.Согласно изобретению, заявленный метод состоит в том, что применяют основную терапию и дополнительно, одновременно вводят per os 5α-фуростан-3β,22,26-триол-3-[O-β-D-глюкопиранозил(1→2)-β-D-глюкопиранозил(1→4)-β-D-галактопиранозил]-26-O-β-D-глюкопиранозил), два раза в день, и 3-O-[β-D-глюкопиранозил-(1→2)]-[β-D-глюкопиранозил(1→3)]-[β-D-глюкопиранозил-(1→4)]-β-D-галактопиранозил-[(25R)-5α-фуростан-2α, 3β, 22α, 26-тетраол]-26-O-β-D- глюкопиранозил,один раз в день, оба средства вводятв дозе 50 мг, с первого дня клинических проявлений, за 30 минут до еды, в течение 3 месяцев.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20120138A MD596Z (ru) | 2012-10-09 | 2012-10-09 | Метод лечения хронического вирусного гепатита С у детей |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20120138A MD596Z (ru) | 2012-10-09 | 2012-10-09 | Метод лечения хронического вирусного гепатита С у детей |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD596Y MD596Y (en) | 2013-02-28 |
| MD596Z true MD596Z (ru) | 2013-09-30 |
Family
ID=47831233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20120138A MD596Z (ru) | 2012-10-09 | 2012-10-09 | Метод лечения хронического вирусного гепатита С у детей |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD596Z (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD667Z (ru) * | 2013-03-20 | 2014-03-31 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Метод лечения инфекционного мононуклеоза у детей |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2046139C1 (ru) * | 1993-02-02 | 1995-10-20 | Институт генетики АН Республики Молдова | Ингибитор ротавирусов |
| US5846964A (en) * | 1993-07-19 | 1998-12-08 | Tokyo Tanabe Company Limited | Hepatitis C virus proliferation inhibitor |
| MD1875G2 (ru) * | 1999-11-01 | 2002-09-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения острого вирусного гепатита В |
| MD2203G2 (ru) * | 2001-04-11 | 2004-01-31 | Институт Генетики И Физиологии Растений Академии Наук Молдовы | Способ обработки семян перца |
| MD2549G2 (ru) * | 2003-07-18 | 2005-08-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения хронического вирусного гепатита С |
| MD3121G2 (ru) * | 2005-09-15 | 2007-03-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод профилактики вирусного гепатита В |
| MD3477G2 (ru) * | 2007-03-21 | 2008-08-31 | Николае БОДРУГ | Метод лечения хронического вирусного гепатита С |
| MD177Z (ru) * | 2010-01-15 | 2010-11-30 | Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы | Способ обработки абрикоса |
| US20120277266A1 (en) * | 2009-03-30 | 2012-11-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
-
2012
- 2012-10-09 MD MDS20120138A patent/MD596Z/ru not_active IP Right Cessation
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2046139C1 (ru) * | 1993-02-02 | 1995-10-20 | Институт генетики АН Республики Молдова | Ингибитор ротавирусов |
| US5846964A (en) * | 1993-07-19 | 1998-12-08 | Tokyo Tanabe Company Limited | Hepatitis C virus proliferation inhibitor |
| MD1875G2 (ru) * | 1999-11-01 | 2002-09-30 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения острого вирусного гепатита В |
| MD2203G2 (ru) * | 2001-04-11 | 2004-01-31 | Институт Генетики И Физиологии Растений Академии Наук Молдовы | Способ обработки семян перца |
| MD2549G2 (ru) * | 2003-07-18 | 2005-08-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод лечения хронического вирусного гепатита С |
| MD3121G2 (ru) * | 2005-09-15 | 2007-03-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Метод профилактики вирусного гепатита В |
| MD3477G2 (ru) * | 2007-03-21 | 2008-08-31 | Николае БОДРУГ | Метод лечения хронического вирусного гепатита С |
| US20120277266A1 (en) * | 2009-03-30 | 2012-11-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| MD177Z (ru) * | 2010-01-15 | 2010-11-30 | Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы | Способ обработки абрикоса |
Non-Patent Citations (8)
| Title |
|---|
| A.Olinescu, L. Andrieş ,,Tehnici imunologice " Ştiinţa, 1994, Chişinău, p.260-268. * |
| American Gastroenterological Association ,, Medical Position Stateman on the Management of Hepatitis C for children, " 2006 * |
| Dumbrava Vlada-Tatiana. Hepatologie bazată pe dovezi.Ghid practic naţional pentru medici de familie, internişti şi gastroenterologi, Chişinău, 2005, p. 117-120. * |
| Grigorescu M., Pascu O. Tratat de gastroenterologie. Clinică. Editura tehnică, Bucureşti, vol. 2, 1997, p. 368-372. * |
| Guidelines for children, American Association for Study of Liver Deseases (AASLD), 2004 * |
| Guidelines However, American Association for the Study of Liver Diseases (AASLD), 2007. * |
| Бурении Н. Л., Котова Г. Н. Справочник по пчеловодству. Москва: Колос, 1977, с. 366 * |
| Ершов Ф. И. и др. Новый индуктор интерферона, активный при пероральном введении. Вопросы вирусологии, 1986, № 3, т. 31, с. 335-338 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD596Y (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial | |
| Gokmen et al. | Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus | |
| US20210322407A1 (en) | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | |
| JP2022050545A (ja) | 敗血症を処置するための方法および組成物 | |
| US20080113955A1 (en) | Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin | |
| KR20250040723A (ko) | 박출율 보존 심부전의 치료를 위한 의약의 제조에서 Jun 억제제의 용도 | |
| Shoaib et al. | Metformin-mediated mitochondrial protection post-cardiac arrest improves EEG activity and confers neuroprotection and survival benefit | |
| Hatakeyama et al. | Combined treatment of imeglimin (Twymeeg) for aged patient with type 2 diabetes (T2D) | |
| US20230181509A1 (en) | The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease | |
| Tiglis et al. | Rhabdomyolysis-induced acute renal injury in a schizophrenic patient | |
| MD596Z (ru) | Метод лечения хронического вирусного гепатита С у детей | |
| US20230270724A1 (en) | PDE3 inhibitors for treating viral infections | |
| WO2003022292A1 (fr) | Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation | |
| AU2021253866A1 (en) | Methods of treating SARS-CoV-2 infections | |
| RU2738552C1 (ru) | Способ лечения оксалатной нефропатии у детей | |
| CN104284670B (zh) | 用于治疗丙型病毒性肝炎的药剂 | |
| Kago et al. | Everolimus Treatment in a Neonate with Heart Failure Caused by Cardiac Rhabdomyomas | |
| Bai et al. | Value of Thymosin α1 Combined With Blood Purification to Increase Successful Rescues of Shock Patients. | |
| RU2445107C2 (ru) | СПОСОБ И СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ГЕПАТИТОВ НА ОСНОВЕ ШТАММОВ Enterococcus faecium M (ВКПМ В-3490) И Enterococcus faecium М-3185 (ВКПМ В-3491) | |
| CN110934888A (zh) | 新型电解质糖苷治疗药物组合物 | |
| Sabiescu et al. | COVID-19 in a Pacient with HIV Inflection-A Case Study | |
| Nemati et al. | Prompt Reversing the Neurologic and Cardiac Manifestations of Valproate Poisoning by Hemodialysis: A Case Report | |
| Cheng et al. | A single-blind randomized controlled trial comparing the efficacy of two doses of oral ibuprofen with intravenous indomethacin in terms of ductus arteriosus closure among premature infants with patent ductus arteriosus: A phase 2A clinical trial | |
| KAMAL et al. | COVID-19 IN A PACIENT WITH HIV INFECTION--A CASE REPORT. | |
| Demiralp et al. | Comorbidity of constrictive pericarditis and hemophilia A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| MK4Y | Short term patent expired |